T-cell leukemia translocation-associated gene protein (TCTA)

T-cell leukemia translocation-associated gene protein (TCTA) is a small, membrane-associated protein expressed ubiquitously in human tissues, with highest levels in the kidney and present in monocytes, osteoclasts, macrophages, and synoviocytes. TCTA is essential for the regulation of osteoclast fusion; peptides derived from its extracellular domain inhibit osteoclastogenesis by blocking the fusion of precursor cells, thereby modulating bone resorption without affecting major differentiation pathways like NFATc1 signaling. A chromosomal aberration involving TCTA (t(1;3)(p34;p21)) is associated with T-cell acute lymphoblastic leukemia (T-ALL), and reduction or loss of TCTA gene copy number suggests a possible tumor suppressor function in small cell lung cancer. While its primary molecular classification is not as a classical therapeutic target like a receptor or enzyme, peptide derivatives highlight potential as a therapeutic modulator in conditions with excessive bone resorption or malignancy[1][2][3][4][5].

Other names

T-cell leukemia translocation-altered gene proteinT-cell leukemia translocation-associated gene proteinTCTA

For TCTA-derived peptides: inhibition of human osteoclastogenesis by blocking precursor cell fusion, not by altering major osteoclastogenic signaling pathways